Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA.
Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA.
Dermatol Clin. 2024 Jul;42(3):339-355. doi: 10.1016/j.det.2024.02.001. Epub 2024 Mar 13.
Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.
针对肿瘤坏死因子-α (TNF-α) 的生物疗法（英夫利昔单抗、阿达木单抗、certolizumab、依那西普）、IL-12 和 IL-23 的 p40 亚单位（乌司奴单抗）、IL-23 的 p19 亚单位（古塞库单抗、替西珠单抗、瑞莎珠单抗）、IL-17A（司库奇尤单抗、依奇珠单抗）、IL-17-RA（布罗达单抗）和 IL-17A 和 IL-17F（倍美莫司单抗）都彻底改变了银屑病的治疗方法。在短期和长期内，risankizumab 与其他口服和注射生物制剂相比，有最高的银屑病面积和严重程度指数 90 分。与 IL-17、IL-12/23 和 TNF-α 抑制剂相比，IL-23 抑制剂具有最低的短期和长期不良事件发生率，以及最有利的长期风险效益比。
